{
    "id": 19496,
    "cites": 17,
    "cited_by": 3,
    "reference": [
        "Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. (2002) \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009dLong-term persistence in use of statin therapy in elderly patients.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d JAMA. July 24, 2002;288(4):455\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c461.",
        "Chandra, A., J. Gruber, J. and R. McKnight (2010): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patient Cost - Sharing and Hospitalization Offsets in the Elderly\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, American Economic Review 100, 193-213.",
        "Contoyannis, P., J. Hurley, P. Grootendorst, S. Jeon and R. Tablyn (2005): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Economics 14, 909-923.",
        "Cooper LA. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009dA 41-year-old African American man with poorly controlled hypertension: review of patient and physician factors related to hypertension treatment adherence\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. JAMA.",
        "March 25, 2009;301(12):1260\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1272 DiMatteo, Robin (2004) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Variations in Patients&apos; Adherence to Medical Recommendations: A Quantitative Review of 50 Years of Research\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Medical Care, vol 42, issue 3 Gellad Walid F., Jerry Grenard, Elizabeth A. McGlynn (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009dA Review of Barriers to Medication Adherence: A Framework for Driving Policy Options\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Technical Report, Goldman, D. P., G. F. Joyce, J. J. Escarce, J. E. Pace, M. D. Solomon, M. Laouri, P. B.",
        "Landsman, and M. Teutsch (2004): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmacy Benefits and the Use of Drugs by the Chronically Ill\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of the American Medical Association 291, 2344-2350.",
        "Hendel, Igal and Aviv Nevo (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Measuring the Implications of Sales and Consumer Inventory Behavior\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, Vol. 74, no 6, 1637-1673 Jha, Ashish K., E. John Orav, and Arnold M. Epstein , \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Low-Quality, High-Cost Hospitals, Mainly in South, Care for Sharply Higher Shares of Elderly Black, Hispanic, and Medicaid Patients,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 30, no. 10 (2011): 1904\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c11 Chien, Alyna T., Kristen Wroblewski, Cheryl Damberg, Thomas R. Williams, Dolores Yanagihara, Yelena Yakunina, and Lawrence P. Casalino, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Do Physician Organizations Located in Lower Socioeconomic Status Areas Score Lower on Pay-for-Performance Measures?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of General Internal Medicine 27, no. 5 (2012): 548\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c54.",
        "Haynes RB, McDonald PM, Garg AX. (2000) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Helping patients follow prescribed treatment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d JAMA. 2002; 288:2880-2883 Krueger, Kem, Bruce Berger and Bill Felkey (2005) Medication Adherence and Persistence: A Comprehensive Review\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Advances in Therapy, Vol 22, No 4 August 2005 Landsman, P. B., W. Yu, X. F. Liu, S. M. Teutsch and M. L. Baerger (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Impact of 3-Tier Pharmacy Benefit Design and Increased Consumer Cost-sharing on Drug Utilization.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Journal of Managed Care 11, 621-628.",
        "Manning, W. G., J. P. Newhouse, N. Duan, E. B. Keeler, A. Leibowitz, and M. S. Marquis (1987) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The American Economic Review 77, 251-277.",
        "Moran, J. R. & Simon, K. I. (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Income and the Use of Prescription Drugs by the Elderly.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Human Resources, XLI, 2, 411-432.",
        "Miura T, Kojima R, Mizutani M, Shiga Y, Takatsu F, Suzuki Y. Effect of digoxin noncompliance on hospitalization and mortality in patients with heart failure in long-term therapy: a prospective cohort study. Eur J Clin Pharmacol. 2001;57:77-83 Newhouse, J. (1993): Free for All: Lessons from the RAND Health Insurance Experiment. Cambridge, MA. Harvard University Press.",
        "Rau, Jordan, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medicare to Penalize 2,211 Hospitals for Excess Readmissions,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Kaiser Health News, August 13, 2012 Roter D. (1995) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Advancing the physician\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s contribution to enhancing compliance.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d J Pharmacoepidemiol. 1995;3:37-48.",
        "Simeonova, Emilia (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Doctors, Patients and the Racial Mortality Gap\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Health Economics, 2013 July 12; 32(5) Simeonova, Emilia (2012) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Marriage, Bereavement and Mortality\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, forthcoming Simonsen, M., L. Skipper, and N. Skipper (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price Sensitivity of Demand for Prescription Drugs: Exploiting a Regression Kink Design\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Mimeo, Aarhus University.",
        "Skipper, Niels (2013) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093On the Demand for Prescription Drugs: Heterogeneity in Price Responses\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Health Economics 22 857-869.",
        "Sleath B, Chewning B, Svarstad B, Roter D. (2000) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patient expression of complaints and adherence problems with medications during chronic disease medical visits.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d J Soc Admin Pharm. 2000;17: 71-80.",
        "Tamblyn, R., R. Laprise, J. A. Hanley et al. (2001): Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons, Journal of the American Medical Association 285, 421-429.",
        "Volpp, Kevin and Mark Pauly (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009dUnited States: Orienting Pay-for-Performance to Patients\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Performance Incentives for Global Health: Potential and Pitfalls, The Brookings Institution Press, Baltimore, MD World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland; 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf."
    ]
}